Aclarion, Inc. (NASDAQ:ACON) Sees Large Decrease in Short Interest

Posted by Shane Hupp on Oct 1st, 2024

Aclarion, Inc. (NASDAQ:ACON – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totalling 279,800 shares, a decrease of 6.0% from the August 31st total of 297,700 shares. Based on an average trading volume of 575,200 shares, the short-interest ratio is presently 0.5 days. Approximately 3.0% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets reiterated a “buy” rating and set a $1.50 price objective (down from $1.60) on shares of Aclarion in a research note on Monday, August 26th.

Check Out Our Latest Stock Report on Aclarion

Aclarion Price Performance

Shares of ACON stock opened at $0.18 on Tuesday. Aclarion has a 12-month low of $0.16 and a 12-month high of $9.90. The firm has a 50-day moving average price of $0.23 and a 200 day moving average price of $0.28.

Aclarion (NASDAQ:ACON – Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. Aclarion had a negative net margin of 10,967.15% and a negative return on equity of 910.84%. The company had revenue of $0.01 million during the quarter. On average, research analysts predict that Aclarion will post -0.99 EPS for the current year.

Institutional Trading of Aclarion

An institutional investor recently bought a new position in Aclarion stock. Virtu Financial LLC purchased a new position in shares of Aclarion, Inc. (NASDAQ:ACON – Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned approximately 1.40% of Aclarion as of its most recent SEC filing. Institutional investors and hedge funds own 7.52% of the company’s stock.

About Aclarion

(Get Free Report)

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.